Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis

Overview of attention for article published in Journal of Neurology, August 2012

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

policy: 2 policy sources
twitter: 5 X users
facebook: 3 Facebook pages

wikipedia: 2 Wikipedia pages
video: 2 YouTube creators

Citations

dimensions_citation: 101 Dimensions

Readers on

mendeley: 303 Mendeley

Summary Policy documents X Facebook Wikipedia YouTube Dimensions citations

So far, Altmetric has seen 3 policy documents that reference this research output.

Cannabis-based medicinal products : C: Spasticity

Cited by National Institute for Health and Care Excellence on 16 Sep 2020

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Cannabis-based medicinal products : B: Chronic pain

Cited by National Institute for Health and Care Excellence on 08 Nov 2019

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Delta-9-tetrahydrocannabinol/Cannabidiol for Spasticity in Multiple Sclerosis: Clinical Effectiveness and Guidelines

Cited by Canadian Agency for Drugs and Technologies in Health on 05 May 2016

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.